Combination of Yondelis (ET-743) and oxaliplatin in experimental ovarian cancer.

被引：0
|
作者：
Erba, E
Colombo, T
Ubezio, P
Ferrarese, L
Matera, G
Falcioni, C
Faircloth, G
Jimeno, J
D'Incalci, M
机构：
[1] IM Mario Negri, Milan, Italy
[2] PharmaMar R&D, Boston, MA USA
[3] PharmaMar R&D, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6264S / 6264S
页数：1
相关论文
共 50 条
  • [41] Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro
    Donald, S
    Verschoyle, RD
    Greaves, P
    Orr, S
    Jimeno, J
    Gescher, AJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (04) : 305 - 312
  • [42] Tumor control and objective responses:: single-center experience with Ecteinascidin-743 (ET-743, Yondelis), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas
    Huygh, G
    Schöffski, P
    Wildiers, H
    Dumez, H
    Van Oosterom, AT
    Jimeno, JM
    Selleslagh, J
    Sciot, R
    De Wever, I
    ANNALS OF ONCOLOGY, 2005, 16 : 311 - 312
  • [43] Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
    Jan-Hendrik Beumer
    Tessa Buckle
    Mariet Ouwehand
    Niels E. F. Franke
    Luis Lopez-Lazaro
    Jan H. M. Schellens
    Jos H. Beijnen
    Olaf van Tellingen
    Investigational New Drugs, 2007, 25
  • [44] Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
    Twelves, C
    Hoekman, K
    Bowman, A
    Vermorken, JB
    Anthoney, A
    Smyth, J
    van Kesteren, C
    Beijnen, JH
    Uiters, J
    Wanders, J
    Gomez, J
    Guzmán, C
    Jimeno, J
    Hanauske, A
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (13) : 1842 - 1851
  • [45] Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
    J. H. Beumer
    J. M. Rademaker-Lakhai
    H. Rosing
    L. Lopez-Lazaro
    J. H. Beijnen
    J. H. M. Schellens
    Investigational New Drugs, 2005, 23 : 429 - 436
  • [46] Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro
    Sarah Donald
    Richard D. Verschoyle
    Peter Greaves
    Samantha Orr
    Jose Jimeno
    Andreas J. Gescher
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 305 - 312
  • [47] Ecteinascidin-743 (ET-743), a marine natural compound, shows antitumor activity against human ovarian carcinoma xenografts.
    Valoti, G
    Nicoletti, MI
    Jimeno, J
    Faircloth, G
    Giavazzi, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S39 - S39
  • [48] In human tumor xenografts the resistance to ET-743 or to cisplatin can be overcome by giving the two drugs in combination
    D'Incalci, M
    Colombo, T
    Giavazzi, G
    Nicoletti, I
    Erba, E
    Ubezio, P
    Meco, D
    Riccardi, R
    Jimeno, J
    Faircloth, G
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S34 - S34
  • [49] A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma.
    Krasner, CN
    McMeekin, S
    Chan, S
    Braly, P
    Kaye, S
    Provencher, D
    Klecz, J
    Michiels, B
    Van de Velde, HV
    Gore, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 460S - 460S
  • [50] A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors
    Chuk, Meredith K.
    Aikin, Alberta
    Whitcomb, Trish
    Widemann, Brigitte C.
    Zannikos, Peter
    Bayever, Eliel
    Balis, Frank M.
    Fox, Elizabeth
    PEDIATRIC BLOOD & CANCER, 2012, 59 (05) : 865 - 869
12345